エストニア - エストニア語 - Ravimiamet

krka d.d. novo mesto - klaritromütsiin - suukaudse suspensiooni graanulid - 125mg 5ml 60ml 1tk

エストニア - エストニア語 - Ravimiamet

viatris sia - klaritromütsiin - suukaudse suspensiooni graanulid - 25mg 1ml 60ml 1tk; 25mg 1ml 100ml 1tk

エストニア - エストニア語 - Ravimiamet

viatris sia - klaritromütsiin - infusioonilahuse kontsentraadi pulber - 500mg 1tk

エストニア - エストニア語 - Ravimiamet

krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 14tk

エストニア - エストニア語 - Ravimiamet

krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 250mg 14tk

エストニア - エストニア語 - Ravimiamet

globalex pharma oÜ - klonasepaam - tablett - 2mg 30tk

欧州連合 - エストニア語 - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - totsilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosupressandid - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

エストニア - エストニア語 - Ravimiamet

ideal trade links uab - klaritromütsiin - suukaudse suspensiooni graanulid - 25mg 1ml 100ml 1tk

エストニア - エストニア語 - Ravimiamet

accord healthcare b.v. - ondansetroon - süste-/infusioonilahus - 2mg 1ml 4ml 5tk; 2mg 1ml 2ml 5tk; 2mg 1ml 2ml 10tk; 2mg 1ml 4ml 10tk